Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
Provider: Reuters Investment Profile
Provider: Wright Reports
Provider: Sadif Analytics Prime

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

JCL Bioassay Corp Amends Consolidated Mid-year Outlook for FY 2014

Tuesday, 5 Nov 2013 01:30am EST 

JCL Bioassay Corp announced that it has raised its consolidated mid-year outlook for revenue from JPY 880 million to JPY 970 million, ordinary profit from a loss of JPY 46 million to a loss of JPY 23 million, but lowered the outlook for operating profit from a loss of JPY 28 million to a loss of JPY 55 million, net profit from a loss JPY 29 million to a loss of JPY 47 million and earning per share from a loss of JPY 8.99 to a loss of JPY 13.80, for the fiscal year ending March 2014. The positive outlook is due to the increased sales and the cost reduction, and the negative outlook due to the decreased sales in subsidiary. 

Company Quote

13.0 +2.91%
19 Dec 2014